TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00558233

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: YourMeds patient education program
Description: computer-based patient education program about prescription drug safety seen immediately before a healthcare provider visit
Study: NCT03253276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obeticholic acid
Description: Placebo-controlled

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT04491617

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard opioid prescribing
Description: Patients are routinely prescribed opioid medications in addition to non-opioids.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Restrictive opioid prescribing
Description: Patients are prescribed non-opioid pain medications, and will be prescribed opioids only if they request them.
Study: NCT03624790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rRSV A/Maryland/001/11
Description: 10\^5 PFU; delivered intranasally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rRSV A/Maryland/001/11
Description: 10\^5 PFU; delivered intranasally
Study: NCT02490839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose dual therapy (rabeprazole, amoxicillin)
Description: High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)
Description: Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
Study: NCT00944957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir for the first 2 weeks
Description: Patient receives raltegravir and efavirenz placebo during the first 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz for the last 2 weeks
Description: Patient receives efavirenz and raltegravir placebo during the last 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz for the first 2 weeks
Description: Efavirenz and raltegravir placebo for the first 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir for the last 2 weeks
Description: Raltegravir and efavirenz placebo for the last 2 weeks
Study: NCT02025530

Intervention type: OTHER
Intervention: Questionnaire
Description: An indepth interview will be carried out and a structured questionnaire will be completed by both cases and controls

Intervention type: OTHER
Intervention: Questionnaire
Description: An indepth interview will be carried out and a structured questionnaire will be completed by both cases and controls
Study: NCT04601844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Single dose administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Single dose administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Single dose administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Single dose administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Single dose administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Single dose administered SC
Study: NCT02758925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 IV day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90mg/m2 IV day 1-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 1000mg/m2 or 750mg/m2 at day 2 if patients aged more than 70 years or toxicity grade 3/4
Study: NCT02989480

Intervention type: RADIATION
Intervention: PET CT
Description: PET CT scans

Intervention type: RADIATION
Intervention: PET CT
Description: PET CT scans

Intervention type: OTHER
Intervention: Cardiac MRI
Description: Cardiac MRI

Intervention type: OTHER
Intervention: Cardiac MRI
Description: Cardiac MRI
Study: NCT01500863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: single shot of 6500 IU hCG s.c. at the time of triggering

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: single shot of 0.2mg triptorelin s.c. at the time of triggering

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin, estradiol valerate, micronized vaginal progesterone
Description: 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin, hCG
Description: single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
Study: NCT04626453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2-month home moderate-intensity exercise
Description: The 2-month exercise will be conducted at the participants' homes. Participants will be recommended to perform the combined exercise, which consists of the resistance exercise and walking at a faster speed than leisure walking at a moderate-intensity, for 6 days/week. They can decide which day they won't perform the exercise. Participants will be encouraged to do progressive resistance exercise and walking twice a day, once in the morning and the other time in the afternoon. Resistance exercise will be suggested to perform every other day for three days/week and walking as the aerobic exercise will be on alternate days for three days/week.
Study: NCT04144478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web based education
Description: Web based education
Study: NCT02067273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Study: NCT04684004

Intervention type: OTHER
Intervention: To report number of HF events and deaths
Description: In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.

Intervention type: OTHER
Intervention: To report number of HF events and deaths
Description: In these two cohorts of study authors will evaluate at 2 years of follow-up the number of HF events and of deaths.
Study: NCT02374489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle.
Study: NCT02053935

Intervention type: DRUG
Group type: OTHER
Intervention: Dopamine
Description: Each subject will receive a priming dose of dextrose 20% to increase their glucose concentration by 125 mg/dl in the first 15 minutes. Then they will receive variable rates of dextrose 20% infusion to maintain glucose level at 180-220 mg/dl. Then, dopamine (200mg/250ml) will be titrated up to 5 mcg/kg/min with care not to increase blood pressure greater than 160 systolic. Dopamine will be infused for 3 hours.
Study: NCT03265418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioXmark liquid fiducial markers
Description: Before the start of the treatment planning during an extra sigmoidoscopy after enema preparation, 4 liquid marker spots will be placed 1 cm from the tumor; two in the in the cranial and two in the caudal direction of the tumor (4 markers in total per patient).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imaging
Description: As part of standard patient set-up directly before each radiotherapy treatment, kV cone-beam CTs will be acquired. Treatment positioning will be based on the regular clinical decision protocols for treatment of rectal cancer and not on the markers. During treatment potential fiducial movement will be assessed using an externally positioned ultra-sound probe, positioned against the abdominal or perineal skin of the patients depending on de position of the tumor/fiducials in the rectum. For patients in this study 2 orthogonal kV images will be made immediately after each radiation using the electronic portal imaging (EPI) device.~As part of standard clinical practice an MR of the rectum will be made for response evaluation 6-8 weeks after the end of neo-adjuvant chemo-radiotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery or wait-and-see
Description: As part of standard clinical practice patients whose tumor has not responded completely will be operated on 8-12 weeks after the end of neoadjuvant chemo-radiotherapy. Patients with a complete response will be follow-upped according to the wait-and-see protocol.
Study: NCT03422939

Intervention type: OTHER
Intervention: there was no intervention, only separate analyses
Description: We only conducted separate analyses to see if responses differed according to level of experience.

Intervention type: OTHER
Intervention: there was no intervention, only separate analyses
Description: We only conducted separate analyses to see if responses differed according to level of experience.
Study: NCT03322930

Intervention type: DIAGNOSTIC_TEST
Intervention: Rod sensitivity
Description: diagnostic test for rod loss in central retina

Intervention type: DIAGNOSTIC_TEST
Intervention: Rod sensitivity
Description: diagnostic test for rod loss in central retina
Study: NCT02619435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib
Description: Patients will receive regorafenib orally 160 mg once daily for the first 3 weeks of each 4-week cycle.
Study: NCT03244501

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active tSMS
Description: A cylindrical neodymium magnet is placed above the scalp.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active tSMS
Description: A cylindrical neodymium magnet is placed above the scalp.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tSMS
Description: A cylindrical piece of nonferrous metal (brass). This is not attracted to magnets, and is identical in weight and appearance to active magnets.
Study: NCT01595386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: The drug will be bolused at 50mg/m2 followed by a continuous infusion that will start at 50mg/m2 for the first 48 hours and then be tapered as follows: 40mg/m2/day over 24 hours, 30mg/m2/day over 12 hours, 20 mg/m2/day over 12 hours, 10mg/m2/day over 24 hours, then off.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: This will be bolused and infused in the same manner as the hydrocortisone arm to ensure blinding of study arm.
Study: NCT04136457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance training
Description: Subjects perform a period of endurance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Subjects perform a period of resistance training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sprint training
Description: Subjects perform a period of sprint training
Study: NCT02730117

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dialysis with continuous renal replacement therapy
Description: Continuous renal replacement therapy is a form of 24-hour dialysis in the ICU

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialysis with continuous renal replacement therapy
Description: Continuous renal replacement therapy is a form of 24-hour dialysis in the ICU

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mechanical ventilator
Description: Invasive or noninvasive form of respiratory support

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilator
Description: Invasive or noninvasive form of respiratory support
Study: NCT01500863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin, hCG
Description: Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin, recombinant LH
Description: 300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
Study: NCT01199497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1
Description: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Group 2
Description: placebo
Study: NCT03641794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DN1406131
Description: IDO1 and TDO2 inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01341145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: 12-week moderate-intensity aerobic exercise program designed in accordance with the recommended guidelines established by the American College of Sports Medicine
Study: NCT03205189

Intervention type: OTHER
Group type: OTHER
Intervention: Comparison between pre-operative prescription and post-operative prescription
Description: The first group will have a pre-operative prescription delivered during the preoperative anesthesia clinic and the second group will receive the postoperative prescription.

Intervention type: OTHER
Group type: OTHER
Intervention: Comparison between pre-operative prescription and post-operative prescription
Description: The first group will have a pre-operative prescription delivered during the preoperative anesthesia clinic and the second group will receive the postoperative prescription.
Study: NCT02569333

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: iPad with educational video highlighting current guidelines for the management of hospitalized patients with ulcerative colitis.
Study: NCT03189810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods \[Cardenas-Morales et al. 2013\] and the rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz (25 trains, 30 pulses per train, 30 second intertrain interval).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods \[Cardenas-Morales et al. 2013\] and the Sham rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz with the B65 placebo coil (25 trains, 30 pulses per train, 30 second intertrain interval).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Counselling Session
Description: In order to support participants in their abstinence plan, individual weekly sessions of supportive counselling will be administered over the course of the study on 1 time per week over 4 weeks (28 days of abstinence).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Weekly Counselling Session
Description: In order to support participants in their abstinence plan, individual weekly sessions of supportive counselling will be administered over the course of the study on 1 time per week over 4 weeks (28 days of abstinence).
Study: NCT01379430

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP followed by MVA ME-TRAP
Description: AdCh63 ME-TRAP 1x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intramuscularly
Study: NCT01341145

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: 12-week progressive muscle relaxation program (active control)
Study: NCT00714649

Intervention type: DRUG
Group type: OTHER
Intervention: cetuximab
Description: Cetuximab 250mg/m²/week IV before surgery till surgery
Study: NCT02730117

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anti-Bacterial Agents
Description: Antibacterial agents deemed appropriate by physicians in the ICU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Bacterial Agents
Description: Antibacterial agents deemed appropriate by physicians in the ICU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vasopressors
Description: Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressors
Description: Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
Study: NCT04008654

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ERAS Protocol
Description: Preoperative measures:~Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis Avoiding premedication~Intraoperative measures:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia (heating the body, and use of warmed up intravenous fluids)~Postoperative:~Application of midthoracic, epidural anesthesia/analgesia Refraining from use of nasogastric tube Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization Adherence to the protocol, and auditing results

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Conventional care
Description: This group of patients will not receive the specific ERAS protocol but will receive conventional care.
Study: NCT02872207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987516 (Y65-122)
Description: 5 µL in one eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987516 (Y65-118)
Description: 5 µL in one eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control
Description: 5 uL in other eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control
Description: 5 uL in other eye
Study: NCT01379430

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdCh63 ME-TRAP followed by MVA ME-TRAP
Description: AdCh63 ME-TRAP 5x10\^10 vp intramuscularly, MVA ME-TRAP 2x10\^8 pfu intradermal
Study: NCT01383213

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen therapy
Description: patient in group oxygen therapy by Venturi Mask will be treated with oxygen until reaching clinical stability, or criteria of endotracheal intubation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helmet CPAP
Description: patient in group CPAP will be treated with CPAP until reaching clinical stability, or criteria of endotracheal intubation
Study: NCT03986138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadopiclenol
Description: Single intravenous bolus injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gadopiclenol
Description: Single intravenous bolus injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol 1 MMOLE/ML Intravenous Solution
Description: Single intravenous bolus injection
Study: NCT00174928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 0.5 mg/kg/day suspension, orally, once daily for up to 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
Study: NCT03986138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol 1 MMOLE/ML Intravenous Solution
Description: Single intravenous bolus injection
Study: NCT02971735

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobile technology of e-learning (M-TEL)
Description: UME students learn the Top 10 emergent ORL-HNS disorders using the M-TEL including the IM module or the PPS module.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile technology of e-learning (M-TEL)
Description: UME students learn the Top 10 emergent ORL-HNS disorders using the M-TEL including the IM module or the PPS module.
Study: NCT01874054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 90 mg/m2 on Days 1 and 2 of 3-week cycles
Study: NCT02988843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Dose level 1: 1.8 mg/kg every 21 days (up to 180 mg) Dose level -1 :1.2 mg/kg every 21 days ( up to 120 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg every 21 days
Study: NCT00592215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental (mifepristone and misoprostol)
Description: Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours
Study: NCT05683769

Intervention type: GENETIC
Intervention: miRNA
Description: Assessment of miRNA, as potential biomarkers to discriminate erosive hand osteoarthritis from psoriatic arthritis

Intervention type: GENETIC
Intervention: miRNA
Description: Assessment of miRNA, as potential biomarkers to discriminate erosive hand osteoarthritis from psoriatic arthritis

Intervention type: GENETIC
Intervention: miRNA
Description: Assessment of miRNA, as potential biomarkers to discriminate erosive hand osteoarthritis from psoriatic arthritis
Study: NCT00536562

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Cardiac Rehabilitation (CR)
Description: 6-month Comprehensive Cardiac Rehabilitation program consisting of: 1) initial medical assessment by case manager and physician to determine CR strategies; 2) entry exercise stress test; 3) multi-disciplinary assessment and intervention to achieve risk factor targets in nutrition \& psychological services as needed; 4) twice per week supervised exercise training and twice per week home-based exercise following an individualized, progressive prescription; 5) Exit assessment at 6 months.
Study: NCT01114256

Intervention type: PROCEDURE
Intervention: FNA Biopsy
Study: NCT04081974

Intervention type: OTHER
Intervention: Distal leg perfusion
Description: On arrival in the operating room, oximeter pads of a NIRO-200NX (NIRO,Hamamatsu® , Japan) NIRS monitor will be placed on the muscles of the calf bilaterally. Lower extremity NIRS is an added monitoring tool as it is currently not being used in our institutional clinical management. Neither anesthetic nor surgical plans will be altered by the study and are left to the discretion of the attending consultant. Also, perfusion goals may not be altered to the results of the leg NIRS. Therefore, the NIRS display will be covered in the operating room throughout the surgery.